Stem cells following haemorrhagic or ischaemic fetal stroke (STELLAR)

Abstract

We propose that i) collection of sufficient cord blood will be feasible in infants with antenatally diagnosed fetal stroke, and ii) (multiple) autologous intravenous administration of processed umbilical cord blood derived cells in these infants in the newborn period will be safe. This phase I trial will be the first study in the translational pipeline for this neurological condition, and will test the feasibility of cord blood collection, sufficient cell availability and safety of cell administration in this vulnerable group. Following successful completion of this study, an efficacy trial will be planned to determine the efficacy of autologous UCB cell administration in fetal stroke.